CHAMPIONPHOENIXIII results presented at the 62nd Annual ACC Meeting showed that the anticoagulant drug cangrelor was significantly superior to clopidogrel in patients with implanted coronary stents. Cangrelor and clopidogrel interfere with the P2Y12 receptor of platelet surface proteins. There are some clinical limitations to the current drugs that are effective in reducing ischemic events in patients undergoing PCI: slow onset of action, remain active for several days, and are only available in tablet form. In patients requiring interventional therapy with antiplatelet therapy, if the drug is still active, performing surgery may increase the risk of bleeding until the drug activity disappears, delaying the procedure. In addition, oral medication may be ineffective in patients who do not have swallowing or absorption function and require stenting. Cangrelor is administered intravenously and has a rapid onset of action that wears off after 1 hour of intravenous administration. CHAMPIONPHOENIX is a randomized, double-blind trial enrolling 11,000 patients at 153 centers worldwide on cangrelor and clopidogrel in patients with various types of acute coronary syndromes, angina, and other conditions requiring PCI. Exclusion criteria were patients on recent anticoagulant medications including GPIIb/IIIa inhibitors, fibrinolytics, and patients at high risk for bleeding. Prof. Deepak L. Bhatt of Harvard Medical School and Prof. Harrington, chairman of Stanford University Medicine, believe that the broad selection of patients for the study means that the drug could be used in many patients worldwide who have undergone stenting.